<DOC>
	<DOCNO>NCT00253396</DOCNO>
	<brief_summary>The purpose study determine short-acting blood thinner ( low-molecular-weight heparin [ Enoxaparin ] unfractionated heparin ) associate less discomfort bruise give subcutaneous ( skin ) injection plan surgery procedure patient temporarily stop warfarin .</brief_summary>
	<brief_title>Patients Preference With Self-Injection : The PRISM Study</brief_title>
	<detailed_description>Increasing Patient Comfort Compliance : The Bridging Anticoagulation Clinic strive provide high quality care patient require temporary interruption warfarin therapy . An important component optimize patient care minimize patient discomfort perioperative administration short-acting anticoagulant ( LWMH UFH ) use bridge therapy , , turn , may optimize patient compliance treatment . This issue especially relevant patient receive out-of-hospital treatment LMWH UFH 85 % patient taught self-administer medication . This study seek determine less discomfort bruising associate self-injection LMWH UFH . Minimizing Injection Site Bruising : No study , knowledge , assess characteristic clinical importance bruising patient receive subcutaneous LMWH UFH . Thus , evidence support association bruise discomfort . To bridge gap knowledge , document injection site course study measure amount bruise observe use standardized photographic methodology . Injection site bruise potential cause medical problem injection site hematoma develop , become infected cause long-term discomfort .</detailed_description>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<criteria>1 . Patient receive warfarin therapy target international normalized ratio ( INR ) 2.03.5 2 . Patient require temporary interruption warfarin elective surgery procedure . 1 . History allergy heparin , include heparininduced thrombocytopenia ( HIT ) 2 . Bridging anticoagulation low molecular weight heparin ( LMWH ) unfractionated heparin ( UFH ) indicate 3 . Impaired cognitive function language barrier 4 . Creatinine clearance &lt; 30 ml/min 5 . Patient decline consent 6 . Patient &lt; 18 year age . 7 . Patient willing able self inject . 8 . Patient significant visual hand motor impairment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>warfarin</keyword>
	<keyword>clinical trial</keyword>
	<keyword>pain measurement</keyword>
	<keyword>heparin</keyword>
	<keyword>heparin , low-molecular-weight</keyword>
	<keyword>Anticoagulants</keyword>
</DOC>